Why the study?
Does doxorubicin produce tumor regression in children with malignant solid tumors?
Population
35 children with malignant solid tumors
Design
Case_series
Authors
Loading...
Early signal of activity in pediatric tumors; leaves open confirmation of benefit, dosing, and safety in controlled trials.
Does doxorubicin produce tumor regression in children with malignant solid tumors?
Doxorubicin administered at 50 mg/sq m at two-week intervals is effective for tumor regression in pediatric solid tumors while allowing adequate time for toxicity evaluation.
Charles B. Pratt (1974) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: